Trends in Cardiovascular Medicine
Volume 16, Issue 6 , Pages 204-208, August 2006

Cytochrome P450 Epoxygenase CYP2J2 and the Risk of Coronary Artery Disease

  • Martin Spiecker

      Affiliations

    • Department of Medicine II, St. Josef-Hospital Bochum, Gudrunstrasse 56, 44791 Bochum, Germany
    • ,
  • JamesK. Liao

      Affiliations

    • Vascular Medicine Research, Brigham and Women's Hospital, Cambridge, MA 02139, USA
    • Corresponding Author InformationAddress correspondence to: James K. Liao, Vascular Medicine Research, Brigham and Women's Hospital, 65 Landsdowne Street, Room 275, Cambridge, MA 02139, USA. Tel.: (+1) 617-768-8424; fax: (+1) 617-768-8425.

Cytochrome P450 (CYP) enzyme 2J2, an epoxygenase predominantly expressed in the heart, metabolizes arachidonic acid to biologically active eicosanoids. One of the CYP2J2 products, 11,12-epoxyeicosatrienoic acid, has several vasoprotective effects. A frequent promoter polymorphism of CYP2J2 decreases gene expression and is associated with coronary artery disease. This association supports the vascular protective role of CYP-derived eicosanoids in cardiovascular disease.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1050-1738(06)00066-1

doi:10.1016/j.tcm.2006.04.001

Trends in Cardiovascular Medicine
Volume 16, Issue 6 , Pages 204-208, August 2006

Article Tools

* Image Usage & Resolution